
Aclarion Inc (ACON) Stock Forecast & Price Target
Aclarion Inc (ACON) Analyst Ratings
Bulls say
Aclarion Inc has demonstrated significant commercial momentum through the establishment of multiple agreements with prominent healthcare institutions, including the Spine Institute of Louisiana and Scripps Health in San Diego. The company reported an impressive 132% year-over-year growth in scans during Q2, coupled with a 76% increase in revenues, signaling a potential for continued upward growth as momentum builds. With the accelerating uptake of its Nociscan SaaS platform, Aclarion positions itself favorably within the healthcare technology sector, enhancing its prospects for future revenue generation.
Bears say
Aclarion Inc faces significant challenges that contribute to a negative outlook on its stock, primarily stemming from slower-than-anticipated traction with insurance payers, which could negatively impact revenue growth. Additionally, the company has adjusted its FY25 earnings per share estimate to $(15.08), reflecting an increase in marketing and administrative expenses that undermine overall financial performance. Also critical are potential risks related to liquidity, regulatory approvals, commercialization capabilities, and competition, which collectively present substantial uncertainties for the company's operational viability.
This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.
Aclarion Inc (ACON) Analyst Forecast & Price Prediction
Start investing in Aclarion Inc (ACON)
Order type
Buy in
Order amount
Est. shares
0 shares